Key Points A survey presented by vTv Therapeutics found that low blood sugar remains a concern for many adults with type 1 diabetes who use…
October 12, 2026
October 08, 2026
Perspective Therapeutics Wins FDA Fast Track Status for Targeted Therapy in Rare Tumors
Key Points The FDA granted Fast Track designation to PSV359 for adults with FAP-positive solitary fibrous tumors that are locally advanced and unresectable and/or metastatic….
Key Points Enliven Therapeutics reached FDA alignment on the final design of ENABLE-2, its pivotal Phase 3 trial of relcobatinib in previously treated chronic myeloid…
Key Points Korro Bio dosed the first healthy-volunteer cohort in ANCHOR, its Phase 1/2 trial of KRRO-121. Participants in the first cohort received a single…
October 05, 2026
vTv Fully Enrolls Phase 3 Cadisegliatin Trial in Type 1 Diabetes
Key Points vTv Therapeutics has completed enrollment in its Phase 3 CATT1 study of cadisegliatin as an add-on treatment to insulin for adults with type…
October 02, 2026
Surrozen Clears FDA IND Hurdle for DME Drug, Unlocking $95.1 Million Financing Milestone
Key Points The FDA has cleared Surrozen’s investigational new drug application for SZN-8141, enabling clinical development in diabetic macular edema. Surrozen expects to dose the…
October 02, 2026
Addex Therapeutics Brings Back Drug Development Veteran Jean-Philippe Rocher to Advance Pipeline
Key Points Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and a member of its executive management team. Rocher brings more than 30…
September 30, 2026
Capricor Shares Rise as Longer-Term Deramiocel Data Enter FDA Review
Key Points Capricor shares rose in early trading Tuesday after a World Muscle Society poster on 24-month deramiocel data became available. The analysis follows patients…
September 29, 2026
Corbus Pharmaceuticals Doses First Patient in Registrational CRB-701 Throat Cancer Trial
Key Points TEMPO-1 is a randomized study expected to enroll 250 patients with second-line or later OPSCC. The trial will compare CRB-701 with the investigator’s…
September 29, 2026
Vivos Therapeutics Targets $3.6 Million in Annual Cost Savings as Revenue Initiatives Advance
Key Points for VVOS Investors Vivos expects the full effect of its cost reductions to take hold in the fourth quarter of 2026, with additional…
Key Points TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….
September 28, 2026
Daré Bioscience Adds U.S. Patent Protection for DARE-HPV as Phase 2 Trial Advances
Key Points Daré Bioscience announced a new U.S. patent covering topical lopinavir-and-ritonavir formulations for HPV-related cervical conditions. Daré holds an exclusive U.S. license to the…